Advancing Therapeutic Development for Myotonic Dystrophy
Rare diseases, like Myotonic Dystrophy (DM), affect tens of thousands in Europe and present significant challenges in diagnosis, treatment, and clinical trials. ENTRY-DM offers 14 doctoral positions to advance ASO therapies for Myotonic Dystrophy through innovative research.
About the ENTRY-DM Network
ENTRY-DM combines experts in DM research, bioengineering, ASO chemistry, and clinical trials. Through collaborations with multi-sectoral partners, we’re tackling technology transfer challenges and preparing doctoral candidates to make significant contributions in ASO therapeutic development.
Why Join?
•14 Open Doctoral Positions in Translational Research
•Interdisciplinary training in disease mechanisms, ASO design, drug delivery, and clinical trials
•Hands-on experience with bioengineering, clinical assessments, and neuropsychological evaluations
•Collaborate with industry leaders and top researchers
•Access to state-of-the-art labs and cutting-edge research
•Prepare for a career in clinical trials and therapeutic development
Candidates with a strong background in biomedical sciences, bioengineering, or related fields areencouraged to apply.
Application deadline May 30, 2025.
Get more information from the link below.
One PhD position is available at the startup Genartis, in collaboration with the research group of Prof. Delledonne and Prof. Rosatto at the University of Verona:
DC1 Innovative genomic technologies for the advanced characterization of myotonic dystrophy mutations. https://euraxess.ec.europa.eu/jobs/324011 (Genatris, Italy)
DC2 The complexity of DM repeat expansions: new challenges in developing personalised molecular therapeutics https://euraxess.ec.europa.eu/jobs/324039 (UTOV, Italy)
DC3 A new integrated in vitro platform to study DM muscle disease https://euraxess.ec.europa.eu/jobs/324043 (IBEC, Spain)
DC4 Advanced human 3D neuromuscular and cortical models for mechanistic and therapeutic research https://euraxess.ec.europa.eu/jobs/324049 (CECS, France)
DC5 Structure and dynamics of nuclear RNA foci in myotonic dystrophy type 1 and 2 https://euraxess.ec.europa.eu/jobs/324052 (RUMC, the Netherlands)
DC6 The contribution of miRNome alterations to DM1: beyond the Muscleblind sequestration model https://euraxess.ec.europa.eu/jobs/324056 (UVEG, Spain)
DC7 Rescuing disrupted single-cell and neural network activities in human DM neural models using ASO https://euraxess.ec.europa.eu/jobs/324077 (RUMC, the Netherlands)
DC8 Therapeutical potential of ASO inducing skipping of CUGexp-containing exon in myotonic dystrophy https://euraxess.ec.europa.eu/jobs/324410 (AMU, Poland)
DC9 Enhancing the activity of therapeutic ASO by genetic modulation and sequence motif adjuvants https://euraxess.ec.europa.eu/jobs/324418 (UVEG, Spain)
DC10 Novel ASO molecules for the therapy of DM1 https://euraxess.ec.europa.eu/jobs/324425 (CSIC, Spain)
DC11 Development of circulating muscle-specific biomarkers of myotonic dystrophy https://euraxess.ec.europa.eu/jobs/324426 (INSERM, France)
DC12 Circulating biomarkers of brain dysfunction in myotonic dystrophy type 1 https://euraxess.ec.europa.eu/jobs/324434 (INSERM, France)
DC13 Myotonic Dystrophy Type 2 (DM2): Biomarker discovery and correlation to clinical outcomes (WP3) https://euraxess.ec.europa.eu/jobs/324437 (LMU, Germany)
DC14 Participation in clinical trials: the contribution of decision-making cognition in patients with DM1 https://euraxess.ec.europa.eu/jobs/324450 (UPC, France)
